Tag: ide-cel

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Visit website
Immunotherapy Web Featured Images 94

Ide-cel in R/R myeloma: patient-reported outcomes and resistance

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the details of a number of studies investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory (R/R) multiple myeloma patients.

Visit website

Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 61

Subanalysis of KarMMA study (idecabtagene vicleucel in MM) and updated results o...

In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.

Visit website

Impact of age on ide-cel efficacy in the KarMMa trial

Jesus Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the updated results from KarMMa (NCT03361748), a study aiming to evaluate the efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in relapsed/refractory (R/R) multiple myeloma.

Visit website